An investigational bispecific HER2/HER3 antibody leads to clinical responses in patients who harbor fusions in the gene neuregulin 1 (NRG1), including those with metastatic pancreatic ductal adenocarcinoma (PDAC) or metastatic non-small cell lung cancer (NSCLC), according to a new study.
An abstract is unavailable.
An abstract is unavailable.
It’s difficult to imagine starting a cancer treatment path for a patient without first reviewing their molecular test results. This means getting the comprehensive story…
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
